Category: Regulatory Affairs
How to Build Regulatory-Ready Real-World Evidence for Drug and Device Submissions
Real-world evidence (RWE) is reshaping regulatory strategy across drug and device lifecycles. Regulators are increasingly receptive to RWE when it’s reliable, transparent, and fit for purpose — not as a replacement for randomized trials but as a complementary source that can speed decision-making, improve safety monitoring, and support label expansions. For regulatory affairs teams, integrating…
Read More
Regulatory Affairs for Digital Health: Lifecycle Strategies for SaMD, RWE, Cybersecurity, and Global Market Access
Regulatory affairs teams are navigating a faster, more interconnected environment as healthcare products become increasingly digital and data-driven. Keeping pace requires a shift from one-time submissions to continuous, lifecycle-focused regulatory strategies that center on safety, effectiveness, and patient needs. What’s shaping regulatory priorities– Software as a medical device (SaMD) and digital therapeutics are drawing sustained…
Read More
Strategic Regulatory Affairs: Leveraging RWE, Digital Health, and Lifecycle Strategies to Accelerate Market Access
Regulatory affairs is evolving from a paperwork-driven function into a strategic partner that shapes product development, market access, and lifecycle management. Greater emphasis on data quality, patient input, and digital technologies is changing how companies plan submissions, manage post-market obligations, and demonstrate value to regulators and payers. Key trends reshaping regulatory strategy– Real-world evidence (RWE):…
Read More
Regulatory Reliance and Worksharing: A Practical Guide for Faster Global Market Access
Regulatory reliance and worksharing: a practical guide for faster global access Regulatory authorities around the world are increasingly using reliance and worksharing mechanisms to reduce duplicated effort, speed reviews, and improve access to new medicines and devices. For regulatory affairs teams, understanding how these pathways work and how to prepare submissions that meet multiple authorities’…
Read More
Regulatory Affairs Guide: SaMD, Real-World Evidence, Cybersecurity, Post-Market Surveillance & Global Compliance
Regulatory affairs professionals are navigating a landscape that’s becoming more complex and interconnected. Devices, drugs, and digital health products face higher expectations for safety, transparency, and lifecycle evidence. Whether you manage submissions, post-market surveillance, or global registrations, a proactive regulatory strategy is essential to keep products compliant and commercially viable. Key trends shaping regulatory activity–…
Read More
How to Navigate Modern Regulatory Affairs: Practical Strategies for RWE, Digital Health & Post‑Market Compliance
Navigating Modern Regulatory Affairs: Practical Strategies for Success Regulatory affairs is evolving quickly as regulators, industry, and healthcare providers adapt to new technologies, data sources, and patient expectations. Whether you work on pharmaceuticals, medical devices, combination products, or digital health solutions, understanding current priorities and aligning strategy to them is essential for timely approvals and…
Read More
Regulatory Affairs Today: 6 Practical Priorities for Medtech and Pharma Teams — Data Integrity, Software, RWE & Cybersecurity
Regulatory Affairs Today: Practical Priorities for Medtech and Pharma Teams Regulatory affairs professionals face a shifting landscape where technology, data expectations, and global regulatory cooperation change how products are developed, reviewed, and monitored. Staying proactive reduces review cycles, lowers compliance risk, and speeds patient access. Key trends shaping regulatory strategy– Greater emphasis on data integrity…
Read More
Building RWE Programs for Regulatory Success: High-Value Data, Rigorous Study Design & Early Regulator Engagement
Real-world evidence (RWE) is reshaping regulatory strategy across drugs, biologics, and medical devices. Regulators increasingly accept data from routine clinical practice, registries, and digital health tools to support labeling changes, safety monitoring, and even initial approvals. For regulatory affairs teams, building robust RWE programs isn’t optional — it’s a strategic imperative. Why RWE matters for…
Read More
How to Make Real-World Evidence Regulatory-Ready: Design, Governance & Early Engagement for Successful Submissions
Real-world evidence (RWE) is reshaping how regulatory affairs teams plan, prepare, and defend product submissions. Regulators are increasingly accepting RWE to support label expansions, safety monitoring, and even primary efficacy claims for certain products. To maximize RWE’s regulatory value, teams must combine sound study design, rigorous data governance, and proactive regulatory engagement. What makes RWE…
Read More
Regulatory Affairs Playbook: AI/ML, RWE, Cybersecurity & Lifecycle Strategy for Pharma, MedTech & SaMD
Regulatory Affairs: Navigating a Rapidly Evolving Landscape Regulatory affairs professionals are facing an expanding and increasingly complex set of expectations as regulators emphasize patient safety, product quality, and faster access to innovation. Whether working with pharmaceuticals, biologics, medical devices, or software-as-a-medical-device (SaMD), staying ahead requires a pragmatic, risk-based approach and strong cross-functional collaboration. Top trends…
Read More